Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Country/Region as subject
Language
Journal subject
Affiliation country
Publication year range
1.
Vox Sang ; 117(3): 346-353, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34558082

ABSTRACT

BACKGROUND AND OBJECTIVES: Balancing blood supply safety and sufficiency is challenging in malaria-endemic countries where the risk of transfusion-transmitted malaria (TTM) is ever-present. In support of reducing this risk, our study aimed at evaluating the performance of the Sysmex XN-31 analyser in blood donor malaria screening, as compared with current practice in Malawi. MATERIALS AND METHODS: This prospective observational study was conducted on remnant venous donor blood samples collected at Malawi Blood Transfusion Service donation sites countrywide for routine blood-borne pathogen screening. XN-31 results were compared with routine thick smear malaria microscopy, using expert microscopy (phase 1 and 2) plus qualitative malaria polymerase chain reaction (PCR) (phase 2) to adjudicate discrepancies. RESULTS: XN-31 detected malaria in 614 (11.6%) of 5281 study samples compared with 341 (6.5%) for routine microscopy. Of the 273 discrepant samples, 60 smears (phase 1) could not be retrieved for expert microscopic review. Expert microscopy confirmed the XN-31 positivity in 78.8% (149/189) and 91.7% (22/24) of discrepant samples in phase 1 (n = 4416) and phase 2 (n = 975), respectively, with two cases requiring PCR testing, confirming one each as positive and negative, giving sensitivities of 100% and 75% and specificities of 99.9% and 100%, respectively, for XN-31 and routine microscopy. CONCLUSION: The automated Sysmex XN-31 analyser's high sensitivity and specificity, ability to detect all Plasmodium species and high throughput with rapid turnaround-time, overcomes many of the limitations of currently available diagnostic tests, making it well-suited for malaria screening of donated blood in malaria-endemic countries in support of TTM risk reduction.


Subject(s)
Blood Donors , Malaria , Blood Safety , Blood Transfusion , Humans , Malaria/diagnosis , Malawi
2.
BMC Med ; 19(1): 303, 2021 11 19.
Article in English | MEDLINE | ID: mdl-34794434

ABSTRACT

BACKGROUND: By August 2021, the COVID-19 pandemic has been less severe in sub-Saharan Africa than elsewhere. In Malawi, there have been three subsequent epidemic waves. We therefore aimed to describe the dynamics of SARS-CoV-2 exposure in Malawi. METHODS: We measured the seroprevalence of anti-SARS-CoV-2 antibodies amongst randomly selected blood transfusion donor sera in Malawi from January 2020 to July 2021 using a cross-sectional study design. In a subset, we also assessed in vitro neutralisation against the original variant (D614G WT) and the Beta variant. RESULTS: A total of 5085 samples were selected from the blood donor database, of which 4075 (80.1%) were aged 20-49 years. Of the total, 1401 were seropositive. After adjustment for assay characteristics and applying population weights, seropositivity reached peaks in October 2020 (18.5%) and May 2021 (64.9%) reflecting the first two epidemic waves. Unlike the first wave, both urban and rural areas had high seropositivity in the second wave, Balaka (rural, 66.2%, April 2021), Blantyre (urban, 75.6%, May 2021), Lilongwe (urban, 78.0%, May 2021), and Mzuzu (urban, 74.6%, April 2021). Blantyre and Mzuzu also show indications of the start of a third pandemic wave with seroprevalence picking up again in July 2021 (Blantyre, 81.7%; Mzuzu, 71.0%). More first wave sera showed in vitro neutralisation activity against the original variant (78% [7/9]) than the beta variant (22% [2/9]), while more second wave sera showed neutralisation activity against the beta variant (75% [12/16]) than the original variant (63% [10/16]). CONCLUSION: The findings confirm extensive SARS-CoV-2 exposure in Malawi over two epidemic waves with likely poor cross-protection to reinfection from the first on the second wave. The dynamics of SARS-CoV-2 exposure will therefore need to be taken into account in the formulation of the COVID-19 vaccination policy in Malawi and across the region. Future studies should use an adequate sample size for the assessment of neutralisation activity across a panel of SARS-CoV-2 variants of concern/interest to estimate community immunity.


Subject(s)
COVID-19 , SARS-CoV-2 , Antibodies, Viral , Blood Donors , COVID-19 Vaccines , Cross-Sectional Studies , Humans , Pandemics , Seroepidemiologic Studies
SELECTION OF CITATIONS
SEARCH DETAIL